Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $0 | $0 | $0 |
| - Cash | $0 | $1 | $3 | $7 |
| + Debt | $3 | $3 | $3 | $0 |
| Enterprise Value | $6 | $2 | $1 | -$7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | $0 | -$3 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$5 | -$0 | -$5 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$6 | -$0 | -$4 | -$5 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.13 | -2.37 | -1.62 | -2.64 |
| % Growth | 10.1% | -46.3% | 38.6% | – |
| Operating Cash Flow | -$4 | -$6 | -$3 | -$3 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$4 | -$6 | -$3 | -$3 |